The company recently released its 2025 Mid-to-Long Term Development White Paper, which clearly outlines the company’s goal of pioneering groundbreaking high-tech products and technologies by 2025, including production, research and development, pre-research, and exploration. In order to achieve industrialized production of new products and break through major technological bottlenecks, the company has unanimously agreed to invest 60 million in upgrading and tackling key technologies in existing production lines. A series of major projects have entered the final phase of clinical registration and approval, key models of manufacturing equipment have begun production, and a batch of research equipment has been introduced and the research and development system has been upgraded to address key technological bottlenecks.

The research and development system underwent a major reorganization, using a laboratory in Beijing as an example. Outdated equipment was eliminated and the research system and personnel were optimized. With guidance from ISO and risk management principles, the R&D department was restructured, modularized, systematized, digitalized, and intelligently operated in terms of research projects, timelines, personnel, and funding. Researchers use an AI system based on neural networks to significantly improve the speed of literature review, and the new electronic research archives not only enhance security and traceability, but also greatly improve the efficiency of researchers. The laboratory has also introduced world-class Roche and Thermo Fisher high-precision research instruments, providing the company with top-notch R&D hardware and environment. The laboratory is currently responsible for the research and development of immunochromatography platforms, chemiluminescence, biochips, and biofermentation processes.